Search
Quinapril
go.drugbank.com/drugs/DB00881ApprovedInvestigational[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. … [L8420] A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999.[L8423]
Mixtures: QUINAPLUS AL 20MG/25MG, QUINAPLUS AL 10MG/12.5MGalpha-Tocopherol acetate
go.drugbank.com/drugs/DB14003ApprovedMoreover, RRR-alpha-tocopherol acetate is a relatively stabilized form of vitamin E that is most commonly used as a food additive when needed [A32451]. … At the moment however, there exists a lack of formal data and evidence to support any such additional indications for vitamin E use.
Mixtures: One A Day Tab, Vitamin A (100,000 Iu) and Vitamin E (20 Iu) Oral Liquid PreparationCategories: Compounds used in a research, industrial, or household settingStem bromelain
go.drugbank.com/drugs/DB12249ApprovedThe primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the … Bromelain itself belongs to a category of protein-digesting enzymes that are obtained commercially from the fruit or stem of pineapples [A27198].
Low affinity immunoglobulin gamma Fc region receptor III-B
go.drugbank.com/bio_entities/BE0000901TargetHumansReceptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG.
Polypeptides: Low affinity immunoglobulin gamma Fc region receptor III-BSynonyms: IgG Fc receptor III-1Low affinity immunoglobulin gamma Fc region receptor II-b
go.drugbank.com/bio_entities/BE0002099TargetHumansReceptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. … Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor.
Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-bSynonyms: IgG Fc receptor II-bTransient receptor potential cation channel subfamily V member 6
go.drugbank.com/bio_entities/BE0005102TransporterTargetHumansCalcium selective cation channel that mediates Ca(2+) uptake in various tissues, including the intestine (PubMed:11097838, PubMed:11248124, PubMed:11278579, PubMed:15184369, PubMed:23612980, PubMed:29258289). Important for normal Ca(2+) ...
Polypeptides: Transient receptor potential cation channel subfamily V member 6Transient receptor potential cation channel subfamily M member 5
go.drugbank.com/bio_entities/BE0020643TargetHumansMonovalent cation-selective ion channel activated by intracellular Ca(2+) in a voltage- and temperature-dependent manner (PubMed:14634208). Mediates the transport of Na(+), K(+) and Cs(+) ions equally well (PubMed:14634208). Activated di...
Polypeptides: Transient receptor potential cation channel subfamily M member 5Synonyms: Long transient receptor potential channel 5Amisulpride
go.drugbank.com/drugs/DB06288ApprovedInvestigationalAmisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. … [L32764] Amisulpride is also used as an antiemetic agent.
Categories: Dopamine D2 Receptor Antagonists, Serotonin Receptor AntagonistsLevoleucovorin
go.drugbank.com/drugs/DB11596ApprovedInvestigationalAs methotrexate functions as a DHFR inhibitor to prevent DNA synthesis in rapidly dividing cells, it also prevents the formation of DHF and THF. … As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side
Categories: Compounds used in a research, industrial, or household settingDibotermin alfa
go.drugbank.com/drugs/DB11639ApprovedInvestigationalDibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2) derived from a recombinant Chinese Hamster Ovary (CHO) cell line [FDA Label]. … Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse.